Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants

Phase 1 Completed 12 enrolled Fujian Akeylink Biotechnology Co., Ltd.

Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of GST-HG171/ritonavir in healthy participants.

Timeline

Start: 2023-05-12
Primary completion: 2023-06-05
Completion: 2023-08-07

Publications

Li X, Li B, Wang M, Wang J, Lu J, Mao J, Zhang T, Tang Y, Yan W, Li C, Zhang G, Ding Y. Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects. Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0028526. doi: 10.1128/aac.00285-26. Epub 2026 May 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GST-HG171	Small molecule	150 mg	Oral
Subject	Itraconazole	Small molecule	200 mg	Oral
Subject	Ritonavir	Other / unclassified	100 mg	Oral

Indications

No indication recorded.